These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 12499264)

  • 1. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
    Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.
    Kim TG; Kim CH; Won EH; Bae SM; Ahn WS; Park JB; Sin JI
    Immunology; 2004 May; 112(1):117-25. PubMed ID: 15096191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
    Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
    He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
    Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
    Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
    Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
    Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
    Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
    J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
    Herd K; Fernando GJ; Dunn LA; Frazer IH; Lambert P; Tindle RW
    Virology; 1997 Apr; 231(1):155-65. PubMed ID: 9143315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW; Anderson ME; Wu S; Lee JH
    Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.